Business Wire

New Clinical Data Support Nexodyn® AcidOxidizing Solution (AOS) To Reactivate the Physiological Healing Process of Chronic Wounds

Jaa

APR Applied Pharma Research sa (APR), the Swiss independent developer of science driven and patent protected healthcare products, today announces the publication in “Advances in skin & wound care” (April 2018) of the results of a clinical pilot study on the efficacy and tolerability of Nexodyn® AcidOxidizing Solution (AOS), a sprayable Active Cleanser with ancillary antimicrobial activity developed for acute and chronic wound management.

Results suggest how Nexodyn® AcidOxidizing Solution (AOS), thanks to its synergic and distinctive physico-chemical properties, could play a key role in the management of chronic wounds as it promotes effectively wound rebooting by creating the ideal microenvironment to sustain the physiological healing process and favoring an optimized lesion closure.

The pilot study was conducted with a prospective, single-arm design by Prof. Robert Strohal in Austria and engaged 30 patients with critically colonized or locally infected chronic leg ulcers of any origin. Along the study, Nexodyn® AcidOxidizing Solution (AOS) was applied on each leg ulcer at every dress change for 35 days together with a nonadherent gauze and a multi-purpose absorbent dressing.

By the end of the study period, treatment with Nexodyn® AcidOxidizing Solution (AOS) led to the full healing of 37% of the chronic wounds as well as to a significant decrease in wound size (P<.001). Moreover, thanks to Nexodyn® AcidOxidizing Solution (AOS) active cleansing properties, wound-associated infections were eliminated, together with a reduction in pH values and local bioburden covering the wound, whilst no reinfection of any examined wounds was observed during the study.

Based on the pilot study, it can be postulated that the application of Nexodyn® AcidOxidizing Solution (AOS) contributes to normalize the pH value of chronic wounds and influence positively biochemical reactions pivotal for rebooting physiological healing process.

Data also confirm Nexodyn® AcidOxidizing Solution (AOS) favorable safety and tolerability profile, especially relevant in chronic wounds, with no adverse events reported over the study duration, high levels of pain relief and comfort at application as well as wound-associated pain reduction.

Due to demographic changes in developed countries, chronic wound healing represents an emerging healthcare issue both from a clinical and social perspective: health care professionals agree that traditional therapeutic alternatives do not satisfactorily address the complex clinical picture.

According to a new market research, the Global Wound Cleanser Product market is anticipated to grow, from $1504.7 million in 2016 to $2171.4 million by 2023, growing at a CAGR of 5.4% (1)

“Nexodyn could fill the gap with the current demand from health care professionals and patients for a treatment option able to address the wound healing complexity” says Giorgio Reiner, Corporate R&D Director at APR – “as it offers the possibility to actively cleanse the wound, thus creating the ideal conditions for wound rebooting”.

As a science driven developer, APR is committed to provide a growing body of clinical evidence to further delineate Nexodyn® AcidOxidizing Solution (AOS) safety and efficacy profile as a wound rebooter.

Full publication “The Management of Critically Colonized and Locally Infected Leg Ulcers with an Acid-Oxidizing Solution: A Pilot Study” available at: https://journals.lww.com/aswcjournal/fulltext/2018/04000/The_Management_of_Critically_Colonized_and_Locally.5.aspx.

(1) Global Wound Cleanser Product Market – Analysis and Forecast (2016-2023) by BSI Research.

About Nexodyn® AcidOxidizing Solution (AOS)

Nexodyn® AcidOxidizing Solution (AOS) is a sprayable Active Cleanser with an ancillary antimicrobial activity developed for acute and chronic wound management.

A wide array of non-clinical experiments and clinical experiences and studies suggest Nexodyn® AcidOxidizing Solution (AOS) to perform as a Wound Rebooter by creating the ideal microenvironment to sustain the physiological healing process. Rebooting a wound, favoring an optimized lesion closure and ensuring a favorable safety and tolerability profile, is especially relevant with chronic wounds.

Developed based on APR’s proprietary and patented technology TEHCLO®, the product is a newly conceived solution with three main features: highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential (ORP >1.000 mV).

Nexodyn® AcidOxidizing Solution (AOS) is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, vascular ulcers), post-surgical wounds, burns and other lesions.

As observed in non-clinical experiments and clinical experiences, Nexodyn® AcidOxidizing Solution (AOS) has synergic physico-chemical properties sustaining wound rebooting to the benefit of patients and HCPs who can rely on the reactivation of the physiological healing process concomitantly to protection and management of uncontrolled microbial growth. Nexodyn® AcidOxidizing Solution (AOS) shows favorable tolerability, with no pain exacerbation, for prolonged periods of use and across the wound healing continuum.

For more info, please visit: http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/#nexodyn-formula

About APR Applied Pharma Research sa

APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

Contact information

APR Applied Pharma Research s.a.,
Paolo Galfetti (CEO)
T: +41 91 6957020 or email to paolo.galfetti@apr.ch

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

IFF-LMR Naturals Leads Industry with 90 Certified Vegan Natural Extracts16.11.2018 00:15Tiedote

Regulatory News: IFF-LMR, a subsidiary of International Flavors & Fragrances Inc (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) announced their industry-leading position of 90 natural extracts in their portfolio certified vegan by the EVE (Expertise Vegan Europe) VEGAN standards. The certified extracts include Rose EssentialTM, Rose UltimateTM, Blackcurrant Buds Absolute, Ylang Oil Complete, Vetiver Oil Haiti, Patchouli Oil Indonesia, and Geranium Heart Oil, among many others. Bertrand de Preville, General Manager, IFF-LMR said, “Our people are passionate about creating the finest ingredients and together, we are committed to delivering premium, 100% pure and natural extracts. We believe in transparency, environmental management and sustainable development.” Mr. de Preville continued, “This certification of 90 extracts is in line with IFF-LMR’s continuous dedication to our planet, people, plants and animals.” The EVE VEGAN label was selected because it is considered one of the most rigor

Rimini Street Expands Investment and Operations in Asia-Pacific15.11.2018 23:00Tiedote

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that it has expanded its operations in the Asia-Pacific region with the launch of its new subsidiary, Rimini Street New Zealand Limited, and the opening of its new office in Auckland to address the growing demand for Rimini Street’s premium, ultra-responsive support services in New Zealand. Rimini Street’s expansion was announced at a gala event held at The Northern Club in Auckland, where clients, local IT leaders and the special guest of honor, Ambassador Scott P. Brown, the U.S. Ambassador to New Zealand, were hosted by Rimini Street’s general manager for Asia-Pacific, Andrew Powell, and Rimini Street corporate senior executives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005037/en/ Rimini Street launches subsidiary

Sartorius Stedim Biotech and Lonza Modify Relationship for Supply of Cell Culture Media15.11.2018 21:15Tiedote

Sartorius Stedim Biotech (SSB) (Paris:DIM), a leading international supplier of the biopharmaceutical industry, and Lonza announced today that they have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave SSB exclusive sales and marketing rights for certain cell culture media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among others. Under agreements signed today, SSB will continue to offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing. Lonza Pharma & Biotech resumes sales and marketing of all its media products for both manufacturing and research. Customers of both companies will continue to be able to source media products for their specific needs. “We have a long-standing and productive partnership

Intertops Poker Launches its 20 Event Strong SOFT Series for its Recreational Player Base15.11.2018 20:46Tiedote

Intertops Poker has launched a new tournament series aimed and created for its recreational and casual player base, with impressive prizes up for grabs. The Intertops Poker SOFT Series is spread across 20 events and offers a combined prize pool of $24,850, including a $4,100 World Series of Poker Caribbean prize package. The series starts on 19th November and will conclude on 25th November. It is available to players from all countries and markets wanting to test their skills and have fun at the tables. There are a wide range of buy-ins to suit all budgets, and the tournament kicks-off with two $500 freerolls before the series gets underway proper on 20th November. Each SOFT Series event winner will receive an Intertops Poker Soft Series Champion hoodie and a seat at the table for the Champions Tournament. The highlight of the series, the Champions Tournament takes place on 25th November at 6:30pm ET and has a guaranteed World Series of Poker Caribbean prize worth $4,100. The World Ser

Telstra: Capital Planning & Delivery Named PMO of the Year15.11.2018 20:21Tiedote

Today, Project Management Institute (PMI), the world’s leading association for the project, program and portfolio management profession, announced that Telstra: Capital Planning & Delivery (Melbourne, Australia) has been awarded the 2018 PMO of the Year Award. In 2012, Telstra created the Capital Planning and Delivery (CP&D) function as a dedicated capability within the Finance and Strategy organization. Their purpose was clear – support the annual capital investment allocation, prioritization, and planning processes to better support investment programs and projects. Since that time, it has created a single enterprise wide investment gating model, created a sponsorship engagement model going from 0% of sponsors engaged at the start to 77% today, and enabled a culture of never stopping projects to one that stops non-viable efforts. With many other accomplishments, the core was a cultural transformation. Engagement of sponsors, enabling project management development opportunities and c

Acuris Risk Intelligence and FinScan® Announce Global Strategic Partnership15.11.2018 19:12Tiedote

Acuris Risk Intelligence, an independent provider of data intelligence for Anti-Money Laundering (AML), Anti-Corruption and Cyber Security; and FinScan, a global leader in AML compliance solutions, have joined forces to deliver an integrated platform for seamless and efficient watch list screening and customer due diligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005681/en/ FinScan provides advanced sanctions, Politically Exposed Persons (PEP) and adverse media screening solutions for organisations worldwide. Its intelligent matching technology drastically reduces false positives and the risk of missing true hits. By combining FinScan’s accuracy and scalability with Acuris Risk Intelligence’s specialised knowledge, the partnership enables clients to screen customers and vendors against any high-risk or sanction lists using the deployment method of their choice. Joel Lange, managing director at Acuris Risk Intel

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme